HIV Infections — HIV Non Occupational Post-Exposure Prophylaxis (PEP)
Citation(s)
A Phase IV Open-Label Evaluation of Safety, Tolerability and Patient Acceptance of Raltegravir (MK-0518) Combined With a Fixed-Dose Formulation of Tenofovir Following Potential Exposure to HIV-1